Clough Capital Partners L P lowered its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 21.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,100 shares of the biotechnology company’s stock after selling 1,900 shares during the period. Clough Capital Partners L P’s holdings in bluebird bio were worth $645,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. First Mercantile Trust Co. boosted its stake in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the last quarter. Berkeley Capital Partners LLC purchased a new position in bluebird bio during the first quarter valued at about $282,000. Teacher Retirement System of Texas purchased a new position in bluebird bio during the first quarter valued at about $291,000. Two Sigma Securities LLC purchased a new position in bluebird bio during the first quarter valued at about $304,000. Finally, Smith Asset Management Group LP purchased a new position in bluebird bio during the first quarter valued at about $311,000.
bluebird bio, Inc. (NASDAQ:BLUE) traded up 0.37% during midday trading on Wednesday, reaching $95.20. 229,693 shares of the company were exchanged. The stock’s market capitalization is $3.90 billion. The firm’s 50 day moving average price is $97.43 and its 200-day moving average price is $83.86. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $123.75.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.76) by $0.08. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. The company had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $1.51 million. Equities analysts forecast that bluebird bio, Inc. will post ($6.72) EPS for the current fiscal year.
WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/bluebird-bio-inc-blue-stake-decreased-by-clough-capital-partners-l-p-updated-updated/1073171.html.
BLUE has been the topic of several research reports. Zacks Investment Research lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. BTIG Research downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $37.05 to $108.25 in a research report on Friday, June 30th. Wedbush reiterated an “outperform” rating and issued a $100.00 target price (down from $121.00) on shares of bluebird bio in a research note on Friday, June 23rd. Cowen and Company restated an “outperform” rating on shares of bluebird bio in a research note on Friday, June 9th. Finally, BidaskClub upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $100.02.
In other news, insider Philip D. Gregory sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $99.04, for a total value of $148,560.00. Following the transaction, the insider now directly owns 37,279 shares in the company, valued at approximately $3,692,112.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Daniel Lynch sold 1,000 shares of the stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $90.01, for a total value of $90,010.00. Following the completion of the sale, the director now owns 2,400 shares of the company’s stock, valued at approximately $216,024. The disclosure for this sale can be found here. Insiders have sold 73,745 shares of company stock worth $7,674,783 in the last ninety days. 3.90% of the stock is currently owned by corporate insiders.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.